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Background-—Long chain acyl-CoA synthetases (ACSL) catalyze long-chain fatty acids (FA) conversion to acyl-CoAs. Temporal
ACSL1 inactivation in mouse hearts (Acsl1H/) impaired FA oxidation and dramatically increased glucose uptake, glucose
oxidation, and mTOR activation, resulting in cardiac hypertrophy. We used unbiased metabolomics and gene expression analyses to
elucidate the cardiac cellular response to increased glucose use in a genetic model of inactivated FA oxidation.
Methods and Results-—Metabolomics analysis identified 60 metabolites altered in Acsl1H/ hearts, including 6 related to
glucose metabolism and 11 to cysteine and glutathione pathways. Concurrently, global cardiac transcriptional analysis revealed
differential expression of 568 genes in Acsl1H/ hearts, a subset of which we hypothesized were targets of mTOR; subsequently,
we measured the transcriptional response of several genes after chronic mTOR inhibition via rapamycin treatment during the
period in which cardiac hypertrophy develops. Hearts from Acsl1H/ mice increased expression of several Hif1a-responsive
glycolytic genes regulated by mTOR; additionally, expression of Scl7a5, Gsta1/2, Gdf15, and amino acid-responsive genes, Fgf21,
Asns, Trib3, Mthfd2, were strikingly increased by mTOR activation.
Conclusions-—The switch from FA to glucose use causes mTOR-dependent alterations in cardiac metabolism. We identified
cardiac mTOR-regulated genes not previously identified in other cellular models, suggesting heart-specific mTOR signaling.
Increased glucose use also changed glutathione-related pathways and compensation by mTOR. The hypertrophy, oxidative
stress, and metabolic changes that occur within the heart when glucose supplants FA as a major energy source suggest
that substrate switching to glucose is not entirely benign. ( J Am Heart Assoc. 2015;4:e001136 doi: 10.1161/
JAHA.114.001136)
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I n the heart, long-chain fatty acids (FA) of 14 to 20carbons are the major substrates for energy produc-
tion1,2and provide 60% to 90% of the ATP used for
contraction.3 Cardiac hypertrophy resulting from systemic
hypertension, ischemia, and infarction is associated with a
metabolic switch in fuel substrates, decreasing FA oxidation
while increasing glucose metabolism.4 Whereas some mouse
models suggest that hypertrophy signaling pathways con-
tribute to the switch to glucose metabolism and that
increased glucose use alone is not sufficient to promote
cardiac hypertrophy,5–7 a study of ex vivo working hearts
showed that dependence on glucose precedes functional
heart remodeling in response to hemodynamic stress,8
highlighting the intricacies between cardiac growth and
metabolism.
We have developed a mouse model in which hypertrophy
results from fuel switching from FA to glucose. A cardiomyo-
cyte-specific deficiency of long-chain acyl-CoA synthetase-1
(Acsl1) prevents the use of FA for oxidation. Thus, ACSL1-
deficient hearts (Acsl1H/) depend on the oxidation of
glucose, amino acids, and ketones for contractile energy9 and
progressively develop cardiac hypertrophy.10
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ORIGINAL RESEARCH
ACSL1, a membrane-associated enzyme present on the
mitochondria and endoplasmic reticulum that catalyzes the
activation of long-chain FA to form acyl-CoA, is 1 of 5 closely
related long-chain acyl-CoA synthetase isoforms. ACSL1 is
highly expressed in oxidative tissues like brown adipose tissue
and heart, and depleting cardiac Acsl1 expression results in a
90% decrease in the mitochondrial oxidation of long-chain
acyl-CoAs.9 In contrast, overexpression of ACSL1 in heart
causes toxicity and cell death, probably due to a mismatch
between the production of acyl-CoAs and their incorporation
into downstream pathways.11 Endogenous ACSL1 in heart
directs its acyl-CoA product towards b-oxidation rather than
towards the synthesis of complex lipids.9 Consistent with the
switch to glucose metabolism in Acsl1H/ hearts, uptake of
the FA analog 2-Br[14C]palmitate decreases 35%, while uptake
of 2-deoxy[14C]glucose increases 8-fold.9,10 Although one
might predict that Acsl1H/ hearts have low energy stores,
the cardiac energy sensor AMP-activated kinase (AMPK) is not
activated; instead, the mechanistic target of rapamycin
(mTOR), a kinase that drives cardiac growth by promoting
protein synthesis and enhancing glucose and lipid metabo-
lism,12 is robustly activated.9 mTORC1 is activated by signals
of nutrient availability, including insulin and other growth
factors, amino acids, and adequate energy levels (oxygen
availability and low AMPK activity).13 The hypertrophy that
occurs in Acsl1H/ hearts is primarily mTOR-dependent, as
hypertrophy is blocked after treatment of Acsl1H/ mice
with rapamycin.10 In order to understand the full extent of the
metabolic pathways that change concomitantly with the
forced substrate switch away from FA oxidation, we
performed unbiased gene array and metabolomics analyses.
We asked whether the expression of specific genes would be
altered in a similar fashion to those previously identified as
downstream targets of mTOR in mouse embryo fibroblasts
(MEFs),14 because such changes might reveal previously




The University of North Carolina Institutional Animal Care and
Use Committee approved the mouse protocols. Mice were
housed in a pathogen-free barrier facility (12-hour light/dark
cycle) with free access to water and food (Prolab RMH 3000
SP76 chow). Mice with LoxP sequences inserted on either
side of exon 2 in the Acsl1 gene15 were backcrossed 6 times
to C57Bl/J6 mice and then interbred with mice in which Cre
expression is driven by an a-myosin heavy chain promoter
induced by tamoxifen (B6.Cg-Tg(Myh6-cre/Esr1)1Jmk/J, Jack-
son Labs) to generate tamoxifen-inducible, heart-specific
Acsl1H/ knockout mice.9 At 6 to 8 weeks of age,
Acsl1H/ and littermate Acsl1flox/flox control male mice were
injected i.p. with tamoxifen (75 mg/kg BW; Sigma), dissolved
in corn oil (20 mg/mL) for 4 consecutive days (3 mg/40 g
BW). Subgroups of mice were also injected daily i.p. for
10 weeks with rapamycin (1 mg/kg in PBS, 8% ethanol, 10%
Tween 20, 10% PEG-400; Sigma) or with vehicle alone. Ten
weeks after tamoxifen induction, animals were anesthetized
with 2,2,2-tribromoethanol, and heart ventricles were
removed and snap frozen in liquid nitrogen. Protein content
was determined by the BCA assay (Pierce) with bovine serum
albumin as the standard. Plasma was collected from mice in
5% 0.5 mol/L EDTA.
Immunoblots
Heart homogenates were prepared in isolation buffer
(250 mmol/L sucrose, 10 mmol/L HEPES, 1 mmol/L EDTA,
1 mmol/L dithiothreitol, plus Halt Protease and Phosphatase
Inhibitor Cocktail [1861280, Thermo Scientific]) and crude
mitochondrial and cytosolic fractions were obtained by
differential centrifugation. Total protein lysates were isolated
in lysis buffer (250 mmol/L sucrose, 20 mmol/L Tris, 1%
Triton X-100, 50 mmol/L NaF, 50 mmol/L NaCl, 5 mmol/L
Na4P2O7, plus Halt Protease and Phosphatase Inhibitor
Cocktail). For GLUT1 Western blots, lysates were treated with
PNGase F deglycosylation kit (P0704S; New England Biolabs)
prior to SDS-PAGE.16 Tissue proteins were blotted with
primary antibodies to detect GSK-3b, P-p70 S6 kinase
(Thr389), p70 S6 kinase, P-4E-BP1 (Thr37/46), 4E-BP1, ACSL1
(9315, 9234, 9202, 2855, 9644 and 4047, respectively; Cell
Signaling Technology), VDAC1, PDK4, GLUT1, and GAPDH
(ab15895, ab38242, ab40084, and ab8245, respectively;
Abcam).
Pyruvate Oxidation
Oxidation of pyruvate was performed as previously
described.9 Freshly isolated heart ventricles and livers were
minced and homogenized with 10 up-and-down strokes using
a motor-driven Teflon pestle and glass mortar in ice-cold
buffer (250 mmol/L sucrose, 1 mmol/L EDTA, 10 mmol/L
Hepes, pH 7.4) at a 20-fold dilution (wt/vol). Homogenates
were centrifuged at 500g for 5 minutes. Oxidation was
measured in a 200 lL reaction mixture containing
100 mmol/L sucrose, 10 mmol/L Tris-HCl, 10 mmol/L
KPO4, 100 mmol/L KCl, 1 mmol/L MgCl2-6H2O, 1 mmol/L
L-carnitine, 0.1 mmol/L malate, 2 mmol/L ATP, 0.05 mmol/
L coenzyme A, and 1 mmol/L dithiothreitol (pH7.4) with
5 mmol/L pyruvate (0.2 lCi of [1-14C]pyruvate for PDH
activity or [2-14C]pyruvate for TCA cycle flux). Oxidation
studies measured the production of 14C-labeled carbon
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dioxide (CO2) for 30 minutes without substrate competition in
a 2-well oxidation system, the assay well containing the
reaction mixture with the tissue homogenate, and the
adjoining well containing 1 N NaOH. The reaction was
terminated by adding 70% perchloric acid to the assay well
and the plate was incubated for 1 hour to drive the CO2 into
the NaOH. Radioactivity of CO2 was determined by liquid
scintillation counting.
Oxidative Stress
For glutathione measurements, tissues were homogenized in
5% 5-sulfo-salicylic acid dehydrate to remove protein. Sam-
ples were treated with 2-vinylpyridine to block free GSH and
other thiols present. GSH/GSSG was measured using a
colorimetric kit (K006-H1; Arbor Assays). For measures of
DNA and RNA damage, 8-hydroxy-20deoxyguanosine and 8-
hydroxyguanosine were measured in 250 to 500 ng total
nucleic acids extracted from left ventricles using an enzyme
immunoassay (589320; Cayman Chemical).
Gene Expression Analysis
Total RNA was isolated from heart ventricles (RNeasy Fibrous
Tissues Kit; Qiagen). RNA integrity was verified on an Agilent
BioAnalyzer 2100 (RIN≥9). For microarray analysis, cyanine-5-
labeled cRNA was co-hybridized to the G4122F mouse whole
genome array (Agilent) with equimolar amounts of cyanine-3-
labeled mouse reference RNA17 and scanned on a GenePix
4000B (Axon) with Feature Extraction (v9.5.3.1; Agilent). In at
least 3 of the 4 biological replicates per condition, 9633
probes were present, and these were used for principal
component analysis (PCA), resulting in the identification of a
single wild-type outlier (data not shown). To determine
differentially expressed genes between genotypes, a gene-
level analysis was performed (GeneSpring GX, v12.4) that
incorporated multiple probes (Lowess normalization) into a
single gene value. Genes that were not detected in at least 2
of the biological replicates per genotype were filtered and
removed, resulting in 7610 genes. The gene values were used
for PCA, hierarchical clustering, and significance of microarray
analysis (SAM).18 Functional enrichment on gene clusters
determined the fold enrichment using the Database for
Annotation, Visualization and Integrated Discovery (DAVID).19
For qPCR analysis, cDNA was synthesized (High Capacity
cDNA RT Kit; Applied Biosystems) and 10 ng of cDNA was
added to each qPCR reaction with SYBR Green (Applied
Biosystems) and used to detect amplicons with primers
specific to the gene of interest (Table 1) quantified using a
qPCR thermocycler (BioRad). Results were normalized to the
housekeeping gene Gapdh and expressed as arbitrary units of
2DDCT relative to the control group.
Tissue Sample Preparation and Analysis by Gas
Chromatography-Time of Flight Mass
Spectrometry (GC-TOFMS)
Tissue sample preparation and analysis by GC-TOFMS was
performed as described.20,21 Approximately 50 mg of each
tissue sample was prepared using a 2-step extraction. The
tissue sample was first added with 50 lL of the first-step
extraction solvent (chloroform:methanol:water; 1:2.5:1) and
homogenized for 6 minutes in a bullet blender (BIOBOXTM;
Next Advance, Inc). The sample was extracted with another
250 lL of the first-step extraction solvent, and centrifuged
at 16 750 9 g for 20 minutes at 4°C. A 100 lL aliquot of
the supernatant was transferred to a GC sampling vial. At
the second step, the deposit of tissue was extracted with
300 lL methanol. After centrifuging at 13 200 rpm for
20 minutes at 4°C, a 100 lL aliquot of supernatant was
transferred to the same GC vial. After vortexing, the samples
were spiked with 2 internal standards (10 lL heptadecanoic
acid at 1 mg/mL and 4-chlorophenylalanine at 0.3 mg/mL)
and were vacuum dried at room temperature. The residue
was derivatized using a 2-step procedure. First, 80 lL
methoxyamine (15 mg/mL in pyridine) was added to the vial
and kept at 30°C for 90 minutes. Then, 80 lL BSTFA (1%
TMCS) was added to the samples, before being derivatized
at 70°C for 60 minutes.
Each 1 lL aliquot of the derivatized solution was injected
in splitless mode into an Agilent 6890N gas chromatography
coupled with a Pegasus HT time-of-flight mass spectrometry
(GC-TOFMS) (Leco Co). To minimize systematic analytical
deviations, samples from 2 groups were run in alternating
order. Separation was achieved on an Rxi-5ms capillary
column (Crossbond 5% diphenyl/95% dimethyl polysiloxane,
Restek), with helium as the carrier gas at a constant flow rate
of 1.0 mL/min. The temperatures of injection, transfer
interface, and ion source were set to 260, 260, and 210°C,
respectively. The GC temperature programming was set to
2 minutes isothermal heating at 80°C, followed by 10°C/min
oven temperature ramped to 220°C, 5°C/min to 240°C, and
25°C/min to 290°C, and a final 8 minutes maintenance at
290°C. Electron impact ionization (70 eV) at full scan mode
(m/z 40 to 600) was used, with an acquisition rate of 20
spectra/sec in the TOFMS setting.
The data generated in the GC-TOFMS instrument were
analyzed by the ChromaTOF software (v4.33; Leco Co).
Compound identification was performed by comparing the
mass fragments with NIST 05 Standard mass spectral
databases in NIST MS search 2.0 (NIST) software with a
similarity of more than 70% and reference standards. Internal
standards and known artificial peaks caused by noise, column
bleed, or the BSTFA derivatization procedure were removed
from the dataset before statistical analysis.
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Tissue Sample Preparation and Analysis by Liquid
Chromatography-Time of Flight Mass
Spectrometry (LC-TOFMS)
Tissue sample preparation and analysis with LC-TOFMS were
performed as described.21–23 Tissue samples (50 mg) were
homogenized on ice in 500 lL of chloroform/methanol/
water (1:2.5:1, v/v/v). Samples were then centrifuged at
16 250 9 g for 10 minutes at 4°C, and a 150 lL aliquot of
the supernatant was transferred to an LC sampling vial
containing an internal standard (10 lL L-4-chloro-phenylala-
nine in water, 5 lg/mL). The deposit was re-homogenized
with 500 lL of methanol, and a 150 lL aliquot of supernatant
was added to the same vial. The extract was centrifuged at
13 000 rpm for 20 minutes, and the supernatant was used
for LC-TOFMS analysis.
An Agilent HPLC 1200 system equipped with a binary
solvent delivery manager and a sample manager (Agilent
Corporation) was used with chromatographic separations
performed on a 4.69150 mm 5 lm Agilent ZORBAX Eclipse
XDB-C18 chromatography column. The LC elution conditions
were optimized as follows: isocratic at 1% B (0 to 0.5 min-
utes), linear gradient from 1% to 20% B (0.5 to 9.0 minutes),
20% to 75% B (9.0 to 15.0 minutes), 75% to 100% B (15.0 to
18.0 minutes), isocratic at 100% B (18.0–19.5 minutes);
linear gradient from 100% to 1% B (19.5 to 20.0 minutes)
and isocratic at 1% B (20.0–25.0 minutes). Here, A=water
with 0.1% formic acid and B=acetonitrile with 0.1% formic
acid. The column was maintained at 30°C. A 10 lL aliquot
sample was injected onto the column. Mass spectrometry
was performed using an Agilent model 6220 MSD TOF-MS
equipped with a dual sprayer electrospray ionization source
(Agilent Corporation). The system was tuned for optimum
sensitivity and resolution using an Agilent ESI-L low concen-
tration tuning mix in both positive (ES+) and negative (ES)
electrospray ionization modes. An Agilent API-TOF reference
mass solution kit was used to obtain accurate mass TOF data
in both positive and negative modes. The TOF MS was
operated under the following optimized conditions: (1) ES+
mode, capillary voltage 3500 V, nebulizer 45 psig, drying gas
temperature 325°C, drying gas flow 11 L/min, and (2) ES
mode, similar conditions as ES+ mode except the capillary
voltage that was adjusted to 3000 V. The TOF-MS is
calibrated routinely in ES+ and ES modes using the Agilent
ESI-L low concentration tuning mix. During metabolite profil-
ing experiments, both plot and centroid data were acquired
for each sample from 50 to 1000 Da over a 25-minute
analysis time.
The resulting .d files were then centroided, deisotoped, and
converted to mzData xml files using the MassHunter Quali-
tative Analysis Program (vB.03.01) (Agilent). After the con-
version, the xml files were analyzed using the open source
Table 1. DNA Oligonucleotide Primer Sequences Used for qPCR Analysis of mRNA Expression in Mouse Heart



















Sequences are listed in the 50 to 30 orientation.
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XCMS package (v1.24.1) (http://metlin.scripps.edu), which
runs in the statistical package R (v.2.12.1) (http://www.r-
project.org), to pick, align, and quantify features (chromato-
graphic events corresponding to specific m/z values and
retention times). The created .tsv file was opened using Excel
software and saved as an .xls file. The resulting data sheet
was used for further multivariate and univariate statistical
analysis. Metabolite annotation was performed by comparing
the accurate mass (m/z) and retention time (Rt) of reference
standards in our in-house library and the accurate mass of
compounds obtained from the web-based resources such as
the Human Metabolome Database (http://www.hmdb.ca/).
Metabolomic Analysis
Metabolite concentrations were analyzed using Metaboana-
lyst (v2.0)24–26 run in the statistical package R (v2.14.0).
Concentrations were log transformed and mean-centered
resulting in a Gaussian distribution of metabolite concentra-
tions. The normalized data was used for PCA and partial least
squares discriminant analysis (PLS-DA). A moderated
t-statistic model (SAM)18 was used to identify metabolites
that were different between genotypes at a false discovery
rate less than 5% and clustered using Euclidean dissimilarity
and average linkage (Partek Genomics Suite, v6.6).
Statistics
Values are expressed as meanstandard error of the mean
(SEM) as indicated. Statistical analysis of qPCR data compar-
ing Acsl1H/ and Acsl1flox/flox for array validation was
performed using a 1-tailed unpaired t test. For studies that
included rapamycin treatments, 2-way ANOVA was used with
the genotype and treatment identified as the sources of
variation. Post-hoc tests were performed with Tukey’s multi-
ple comparisons test. For all tests, P>0.05 was considered
non-significant (ns).
Results
Genomic Analysis Identified Novel Gene
Expression Patterns in Acsl1H/ Ventricles
Acsl1H/ mice have impaired cardiac FA oxidation and
develop spontaneous cardiac hypertrophy due to increased
mTOR activation.10 To explore how the loss of ACSL1 alters
mRNA regulation, we performed a global gene expression
analysis on ventricular RNA isolated from Acsl1H/ and
Acsl1flox/flox mice 10 weeks after tamoxifen treatment, when
ACSL1 protein is completely absent and the ACSL-specific
activity in Acsl1H/ hearts is reduced 90%.9 PCA identified
the genotype as a primary variable contributing to the
differences in global gene expression (Figure 1A, principal
component 1, 33% of the total variance), which was further
confirmed via unsupervised hierarchical clustering (Fig-
ure 2A). Significance analysis of microarrays (SAM) identified
568 differentially expressed genes at a false discovery rate
less than 4.36% (Figures 1B and 2B, Table S1).
In MEFs with increased mTOR activity, the transcription
factors Srepf1 and Hif1a mediate downstream mTORC1
pathways, including lipid biosynthesis, the pentose phosphate
shunt, and glycolysis.14 Activation of mTOR in Acsl1H/
hearts was shown in previous studies10 as well as in the
current work by a 6-fold increase in phosphorylated S6 kinase
(S6K); additionally, variations in the amount of phosphoryla-
tion led to a non-significant 3-fold increase in phosphorylation
of 4E-BP1, a second mTOR target examined (Figure 3A). Given
both the activation of mTOR and the cardiac hypertrophy that
develops in Acsl1H/ hearts,9 we hypothesized that changes
related to mTORC1 and hypertrophy would be reflected at the
mRNA level. In fact, the expression of both Srebf1 and Hif1a
was increased, as well as their respective targets Trib327 and
Pdk4,28,29 which regulate glucose metabolism (Table 2, Table
S1, Figure 3B and 3C). These changes coincide with an 8-fold
higher uptake of 2-deoxy[14C]glucose by Acsl1H/ hearts
compared with controls.10 Consistent with the cardiac
hypertrophy, the hypertrophy-associated gene Myc increased
A B
Figure 1. Global changes in gene expression in Acsl1H/
hearts. A, Principal component analysis (PCA) of global changes
in cardiac gene expression was performed using the levels of 7581
genes in Acsl1flox/flox (red closed circles) and Acsl1H/ (green
closed circles) mice after 10 weeks of rapamycin treatment,
represented by a scatter plot of the first (PC1) vs second principal
component (PC2). Four eigenvectors were calculated for PCA and
data represented in the scatter plot are scaled to unit standard
deviation. Confidence ellipses categorized by genotype represent 2
standard deviations. B, Significance analysis of microarrays (SAM)
plot of observed scores plotted against the expected scores. The
solid line represents observed=expected, whereas the hashed lines
indicate the significance threshold based on D=0.851. The genes
identified as differentially expressed are indicated by red and blue
open circles, indicating higher and lower expression, respectively,
of these genes in Acsl1H/ mouse hearts. The number of
differentially expressed genes, predicted false positives, and the
false discovery rate (FDR) are provided (also see Figure 2A and 2B).
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5- to 6-fold (Table 2, Figure 3B). Growth differentiation factor
15 (Gdf15), one of the most highly up-regulated genes
observed (Table 2, Table S1, Figure 3B), is upregulated by
events that cause oxidative stress in heart and is considered
to be protective against apoptosis and fibrosis.30
Other pathways that were altered by the temporal loss of
cardiac Acsl1 expression included functional clusters that
correlated with differential gene expression (Table 3). The
clusters that increased in Acsl1H/ hearts primarily involved
cellular metabolism (amino acids (eg, Slc7a5; large neutral
amino acid transporter small subunit-1), lipids, flavoproteins,
and several peroxisomal genes), protein synthesis (aminoacyl-
tRNA synthetases and ribosomal genes), and additional genes
involved in cardiac remodeling, such as MuRF1 (Trim63), Abra,
and Cryab. Also increased in Acsl1H/ hearts was the
expression of the tRNA synthetase Lars, as well as several
other tRNA-synthetases (Cars, Nars, Sars, and Aars), consis-
tent with the increases in mTORC1 activity and protein
synthesis. LARS activates mTOR through its non-canonical
role as a GTPase-activating protein for Rag GTPase that
directly activates mTORC1, thereby linking amino acid
metabolism and mTOR activation.
Down-regulated genes in Acsl1H/ hearts relative to
control hearts were primarily genes involved in transcriptional
regulation, such as Ppara, as well as 22 zinc finger genes
(Table 3). Additional functional categories that were down-
regulated included apoptotic regulatory genes and genes
involved in striated muscle development, consistent with the
extensive remodeling observed in Acsl1H/ hearts.
Enhanced Amino Acid Response and Glutathione
S-Transferase Gene Expression in Acsl1H/
Hearts
The shift from FA to glucose as the heart’s primary fuel
substrate has been observed in many models of cardiac
pathology and injury. Whether the substrate switch is adaptive
or maladaptive remains an ongoing debate.31,32 Nevertheless,
because the heart is metabolically resilient, we hypothesized
that the Acsl1H/ mouse model would reveal additional
metabolic pathways not appreciated in previous studies of
hypertrophy or substrate switching. The most up-regulated
genes in Acsl1H/ hearts (range=4- to 38-fold, q-value=0.00;
Table S1) were involved in either the amino acid response33
(Fgf21, Gdf15, Mthfd2, Trib3, Asns) or glutathione metabolism
(Gsta1) (Table 2, Figure 3B). Several human and rodent
models of skeletal muscle mitochondrial myopathy, including
mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episodes (MELAS syndrome), progressive external
ophthalmoplegia, and the deletor mouse, also show a similar
response with upregulation of the same genes.34–36 The
promoter regions of the amino acid responsive genes contain
consensus sequences for the conserved amino acid response
element (AARE); thus, because both Asns and Mthfd2 are
involved in amino acid synthesis, it is likely that an increased
A B
Figure 2. Unsupervised gene clustering. A, Unsupervised hier-
archical clustering was used to reveal natural categories in gene
expression data sets. Expression values from the 7162 genes
detected via microarray analysis were analyzed by sample
clustering using Pearson’s Dissimilarity matrix with average
linkage (Partek Genomics Suite, v6.6). Two primary clusters of
microarray samples were comprised solely of either Acsl1flox/flox
(red) or Acsl1H/ (green) biological replicates. The scale for the
dendrogram represents the distance of clusters by Pearson’s
correlation coefficient. B, Unsupervised clustering of the 568 SAM
positive genes. The expression values from the 568 genes (rows)
from 7 samples (columns) detected as differentially expressed via
microarray analysis were analyzed with hierarchical clustering
using the Euclidian matrix with average linkage (Partek Genomics
Suite, v6.6). As expected based on the 2 class SAM analysis used
to identify differentially expressed genes, we identified 2 primary
clusters of microarray samples comprised solely of either
Acsl1flox/flox (red) or Acsl1H/ (green) biological replicates.
Additionally, the genes portioned into 2 groups of higher (maroon)
or lower (blue) expression across the 2 genotypes. SAM indicates
significance analysis of microarrays.
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reliance on amino acids for energy initiates this response.
Also among the amino acid responsive genes is Fgf21, whose
gene product secreted by liver, skeletal muscle, pancreas, and
adipose tissue regulates glucose and lipid metabolism during
fasting.37 Fgf21 expression was not increased in liver from
Acsl1H/ mice (data not shown) suggesting that the
Table 2. Gene Expression Changes in Acsl1H/ Hearts
mRNA Description Fold Change Microarray Fold Change qPCR
Srebf1 Sterol regulatory element binding transcription factor 1 2.33 2.91**
Hif1a Hypoxia inducible factor 1, alpha subunit 2.22 1.63*
Trib3 Tribbles homolog 3 13.10 13.17**
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 5.20 6.10****
Myc Myelocytomatosis oncogene, transcript variant 1 5.11 6.54**
Gdf15 Growth differentiation factor 15 37.78 76.93****
Fgf21 Fibroblast growth factor 21 30.02 153.17***
Mthfd2 Methylene tetrahydrofolate dehydrogenase 17.79 32.80***
Asns Asparagine synthetase 4.26 17.49**
Gsta1 Glutathione S-transferase, alpha 20.81 14.65**
The relative fold change in gene expression identified via microarray analysis and subsequently validated via qPCR analysis, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
A B
C
Figure 3. mTOR activation and expression of selected genes in ventricles from control and Acsl1H/
mice treated with vehicle or rapamycin for 10 weeks. A, Representative immunoblots from ventricles of
male mice 10 weeks after tamoxifen treatment. The levels of total and phosphorylated (P-p70 S6K
[Thr389], P-4E-BP1 [Thr37/46]) p70 S6K and 4E-BP1 were quantified with ImageJ software, and the ratio of
phosphorylated to total protein is shown (bottom). The values are meanSEM. n=3, *P<0.05. B, Rapamycin
treatment normalized the expression of the amino acid responsive genes Fgf21, Gdf15, Mthfd2, Trib3, Asns,
as well as Gsta1 and the hypertrophy marker, Myc. C, Hif1a and Slc7a5 were also normalized with
rapamycin treatment, whereas other genes altered by the loss of Acsl1 expression were insensitive to
rapamycin. Data are represented by the meanSEM from 6 biological replicates per condition. The
resulting P values from the 2-way ANOVA based on genotype (G), treatment (Tx), and of the interaction (∩)
are indicated: post-hoc test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 Acsl1flox/flox vs Acsl1H/
within vehicle; †P<0.05, ††P<0.01, †††P<0.001, ††††P<0.0001 vehicle vs rapamycin within genotype. ANOVA
indicates analysis of variance; mTOR, mechanistic target of rapamycin; S6K, S6 kinase.
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Table 3. Functional Clustering of Gene Expression Changes in Acsl1H/ Hearts
Functional Cluster Genes ES FE
Increased expression in Acsl1H/
Aminoacyl-tRNA
synthetases
Iars, Cars, Nars, Sars, Aars, Lars, Ubc, Rps2 3.2 8.6
Ribosome Gm10653, Rpl17, Mrpl27, Ubc, Rpl3, Rpl22l1, Mrpl48, Rpl10a, Rps21, Rps2,
Cpeb1, Nhp2, Cryab, Thbs4
2.9 3.7
Flavoproteins Acox1, Aox1, Fdxr, Nqo1, Sardh, Por, Dus2l, Retsat 2.5 4.8
Peroxisome Acox1, Ech1, Mlycd, Hsdl2, Ehhadh, Ephx2, Cat 2.2 5.5
Sarcomere Ankrd23, Acta1, Cryab, Abra, Myh7, Trim63 2.2 5.0






Glul, Adssl1, Asns, Cad 1.5 8.3
Regulation of fatty acid
and lipid metabolism
Srebf1, Mlycd, Agt, Angptl4 1.5 8.8
Decreased expression in Acsl1H/
Transcription regulation Camta1, Ppara, E2F3, Tshz1, Taf1D, Zfp639, Rest, Zfp768, Cxxc1, Max, Taf5L,
Mll5, Myocd, Tsc22D4, Gata6, Tef, Zfp410, Tfdp2, Per1, Hbp1, Zfp687, Rarb,
Thap11, Dedd2, Ccar1, Zfp422, Zfp329, Rcor3, Rcor2, Zfp30, Taf8, Gabpa,
Hmbox1, Zfx, Mecp2, Zfp672, Creb5, Zfp322A, Mbd1, Zbtb43, Zfp579, Zfp770,
Trim33, Ncoa6, Mnt, Pprc1, Phf21A, Mpv17, Zpf612, Mlf1, Csdc2, Pkig, Zpf655,
Neo1, Arid2, Meis2, Cenpf, Lass4
5.8 2.0
Zinc finger region Zfp329, Zfp579, Zfp770, Zfp30, Zfx, Zfp672, Zfp639, Zfp322A, Zfp687, Rest,




Pdp1, Midn, E2F3, Neat1, Bnip3, Rest, Arid2, Zfp768, Cxxc1, Alas1, Mll5, Myocd,
Gata6, Fign, Zfml, Ivd, Tfdp2, Hspa5, Top2B, Dedd2, Luc7L3, Ccar1, Rcor2, Taf8,
Mphosph10, Cenpf, Mbd1, Zfp655, Ppm1K, Ncoa6, Phf21A
3.9 2.2
Ion binding Pdp1, Apobec2, Ppara, Agtpbp1, Dicer1, Adcy6, Pdlim3, Zfp639, Rest, Kcnj12,
Kcnj11, Mll5, Trim8, Zfml, Gata6, Rarb, Zfp687, 2010111I01Rik, Kcnq1, Zfp422,
Zfp329, Car14, Zfp30, Zfx, Zfp322A, Gmpr, Tecr, Mbd1, Trim35, Prune, Zfp655,
Trim33, Ppm1K, Rnf139, Usp20, Zadh2, Pla2G5, Slc39A14, Myl7, Sord, Tshz1,
Zfp612, Egln1, Nhlrc1, Arid2, Zfp768, Cxxc1, Acsl1, Zfp410, Eno3, Efcab2,
Scn5A, Thap11, Mat2A, Rufy1, Zfp672, Creb5, Zbtb43, Ppa2, Micall1, Ick,
Zfp579, Dsg2, Zfp770, Zfp207, Mpped2, Sh3Rf2, Phf21A, Abl2, Bmpr1A
2.9 1.4
Zinc finger Zfp422, Zfp329, Tshz1, Zfp612, Zfp30, Zfx, Zfp672, Creb5, Zfp639, Zfp322A,
Rest, Arid2, Zbtb43, Zfp768, Zfp579, Zfp655, Zfp770, Zfml, Zfp207, Zfp410,
Zfp687
2.9 2.2
Fibronectin, type III Epha4, Fndc5, Myom2, Speg, Cmya5, Obsl1, Neo1, Myom1, Insr 2.3 3.4
Negative regulation of
transcription
Rcor2, Gabpa, Dicer1, Pkig, Mecp2, Bnip3, Cenpf, Zfp639, Rest, Myocd, Per1,
Phf21A, Rarb, Kcnq1, Ednra
1.6 2.1






Pdp1, Alpk2, Stk35, Mecp2, Adrbk2, Ptpn21, Adora1, Ppa2, Gak, Akt1, Epha4, Ick,




Gata6, Dicer1, Dok7, Pdlim3, Egln1, Rarb 1.3 3.1
Genes that were upregulated or down regulated (Figure 1B) were analyzed for functional clustering using DAVID.19,57,58 Each functional cluster is listed with the genes comprising the
cluster, as well as the enrichment score (ES), a measure of significance using a modified Fisher Exact,19,57,58 and the fold enrichment (FE), which represents the increase in the number of
genes present in the differential gene list for a given pathway compared to the expected frequency of genes associated with that pathway in the entire mouse genome.
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increase in Fgf21 expression in the heart was caused by the
loss of Acsl1 activity specifically in cardiac tissue. We
hypothesized that the upregulation of the amino acid
response was secondary to the elevated mTORC1 activity.
Indeed, when we treated mice with the mTOR inhibitor
rapamycin, we observed a marked attenuation of the induced
amino acid responsive genes, including Fgf21, Gdf15, Mthfd2,
Trib3, Asns, and Gsta1 (Figure 3B) as well as Hif1a and the
leucine transporter Slc7a5 (Figure 3C), confirming that their
upregulation was secondary to the elevated mTORC1 activity.
Although Srebp1 is regulated, in part, by mTOR,14 the
increased expression of Srebp1 did not diminish with
rapamycin treatment, nor did the expression of Acot1 and
Acot2 (Figure 3C), which are cytosolic thioesterases that are
upregulated by PPARa and HNFa.38 Major down-regulated
genes that did not respond to rapamycin included: Pfkfb1,
which encodes the regulating enzyme for gluconeogenesis
and glycolysis; Gpr22, which encodes an orphan G-protein
coupled receptor; and Sesn1, which encodes a protein
involved in antioxidant defense (Figure 3C). Consistent with
the transcriptional signature indicative of heightened cellular
stress via increased expression of amino acid responsive
genes, and persistent protein synthesis via mTOR activation in
Acsl1H/ hearts, we also observed an increase in several
genes associated with the amino acid deprivation response,39
including activating transcription factor 3 (Atf3), cysteinyl-
tRNA synthetase (Cars), Kruppel-like factor 10 (Klf10), chro-
mobox homolog 4 (Cbx4), interferon-related developmental
regulator 1 (Ifrd1), arrestin domain containing 4 (Arrdc4), and
seryl-aminoacyl-tRNA synthetase (Sars).
Thus, the global expression analysis of Acsl1H/ ventri-
cles confirms the increase in mTORC1 activity and its
downstream mRNA regulation, together with expected mark-
ers of cardiac hypertrophy. Furthermore, the coordinated
increase in amino acid response-related genes, amino acid
deprivation genes, and glutathione S-transferase/peroxidase
expression (Gsta1/2) appears to represent compensatory
pathways that are activated in response to the enhanced
mTORC1 activity, perhaps to maintain cardiac function by
countering the effect of mTOR signaling on protein synthesis
and the oxidative stress associated with chronic mTOR
activation (see below).
Metabolomic Profiling in Acsl1H/ Ventricles
Confirmed Increased Glycolysis as Well as
Enhanced Cysteine and Glutathione Metabolism
Although much can be inferred from global transcriptional
approaches, advances in metabolomics have offered new
insights into cellular metabolism through the quantitative
analysis of hundreds of metabolites.40 We hypothesized that
preventing hearts from using FA as an oxidative fuel source
would be likely to reveal numerous glycolytic products, while
also providing clues into other pathways altered at the
metabolite level. To measure metabolite changes, we used a
dual platform consisting of GC- and LC-TOFMS that quanti-
tatively measured 157 and 115 metabolites, respectively,
from control and Acsl1H/ hearts. Metabolite concentra-
tions were normalized for each platform independently prior
to statistical analysis (Figure 4). After merging metabolite
concentrations from both platforms into a single dataset, the
platform itself was the highest source of variance (data not
shown); therefore, we analyzed each platform independently
and compared across the 2 genotypes. Similar to the global
transcriptional analysis, both PCA and partial least squares
(PLS) analysis demonstrated that the predominant source of
variance in the metabolite data was genotype, suggesting
that substantial differences exist in the metabolite concen-
trations that are dependent on the genotype of the sample
(Figure 5).
We again used a 2-class SAM algorithm to identify
individual metabolite concentrations that differed between
the 2 groups and identified 47 and 13 species from LC-
TOFMS and GC-TOFMS, respectively (FDR<5%, Figure 6A and
6B). The 60 metabolite concentrations and samples were then
subjected to unsupervised hierarchal clustering (Figure 6C).
As expected, the samples (represented by columns) clustered
based on genotype and the metabolites (represented by rows)
clustered into 2 primary nodes based on the direction of
change. Given the reliance on glucose metabolism in
Acsl1H/ hearts, we were not surprised to find that several
glycolytic metabolites were increased in Acsl1H/ hearts.
Among the metabolites that had increased the most com-
pared with control hearts were the glycolytic metabolites
fructose, fructose 6-phosphate, mannose, mannitol, mannose
6-phosphate, and glucose 6-phosphate; additionally, we
found increased levels of metabolites downstream from the
pentose phosphate pathway (ribitol) and the TCA cycle
(succinate).
To further confirm that glycolysis is indeed increased in
Acsl1H/ hearts, we measured oxidation of [1-14C]- and
[2-14C]pyruvate to assess PDH activity and TCA cycle flux,
respectively. Despite increased Pdk4 mRNA expression
(Table 2), which is generally regarded as indicating depressed
glucose metabolism, PDK4 protein levels did not differ
between Acsl1H/ mice and their control Acsl1flox/flox
littermates (Figure 7A), whereas GLUT1 levels were signifi-
cantly higher in Acsl1 knockout mice (Figure 7B), in agree-
ment with the previously observed increase in glucose intake
with Acsl1 deficiency.10 In addition, compared with controls,
PDH activity and TCA cycle flux were also higher in Acsl1H/
hearts (Figure 7C and 7D), indicating increased use of
pyruvate to produce energy and, thus, higher rates of
glycolysis in ACSL1-deficient hearts.
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In addition to the strong glycolytic signals in Acsl1H/
hearts, a second dominant class of metabolites was amino
acids and intermediates of amino acid metabolism. Amino
acids can function as regulatory molecules in increasing
mTOR activity and its effects on translation and proteolysis. In
particular, sulfur-containing amino acids such as cysteine play
important roles in transcriptional regulation, but also in
controlling the oxidative balance in tissues. Tissue levels of
cysteine are normally maintained to meet the need for both
protein and coenzyme A synthesis, as well as for the synthesis
of the intracellular antioxidant glutathione. To assess whether
glutathione metabolism and oxidative stress were affected by
cardiac-specific Acsl1 deficiency, we first analyzed GSK-3b
translocation from the cytosol to mitochondrial membranes in
control vs Acsl1H/ mice.41 Compared with their control
littermates, Acsl1H/ mice showed a 2-fold increase in GSK-
3b in the mitochondrial fraction, suggesting the presence of
increased oxidative stress in response to cardiac ACSL1
deficiency (Figure 8A). Despite lower levels of 8-hydroxy-
20deoxyguanosine in knockout mice, suggesting less DNA
damage (Figure 8B), cardiac-specific Acsl1 deficiency resulted
in a higher amount of oxidized glutathione (GSSG), and a 15%
lower GSH/GSSG ratio in Acsl1H/ mice, further confirming
the increase in oxidative stress possibly restricted to gluta-
thione metabolism.
Surprisingly, of the 60 differentially expressedmetabolites in
Acsl1H/ hearts, more than 20% (13 metabolites) mapped to
cysteine and glutathione metabolism (Figure 9). Together with
the robust increase in both Gsta1 and Gsta2 expression
(Table 2), the abrogation of Gsta1 activation with rapamycin
(Figure 3B), and the increase in oxidized glutathione and other
oxidative stress markers analyzed (Figure 8), these data
suggest that a compensatory increase in cysteine and glutathi-
one metabolism may be an essential response to minimize the
increased oxidative stress that accompanies glucose-initiated
mTOR-activation and the resulting cardiac hypertrophy.
Discussion
ACSL1 comprises 90% of total ACSL activity in the
heart and directs activated FA towards mitochondrial




Figure 4. Normalization of metabolite concentrations results in Gaussian distributions. Prior to statistical analysis, the metabolite counts
from the LC-TOFMS and GS-TOFMS were log transformed and mean-centered. A, The frequency distributions were plotted with a bin width of
0.5 (green bars) and subsequently fit to a Gaussian distribution curve (solid black line, equation and R2 value as indicated). B, To remove any
potential bin size bias, the same data were analyzed with a cumulative frequency distribution plot. If the data follow a Gaussian distribution, the
cumulative distribution has a sigmoidal shape, as shown here (green line). The non-linear fit is also plotted (dotted line) with the corresponding
R2 value provided. C, Outlier analysis of GC-TOFMS metabolites. Principal component analysis (PCA) of metabolite concentrations from 13 heart
samples measured on the GC-TOFMS platform. There was a single sample that did not cluster with either genotype (highlighted by the blue
circle) and contributed to over 35% of the variance as measured via PCA. This sample was removed from the GC-TOFMS statistical analysis.
GC- and LC-TOFMS indicates gas chromatography and liquid chromatography-time of flight mass spectrometry.
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the substrate used by the heart for energy, but when ACSL1
is absent, FA oxidation decreases more than 90%.9 In
compensation, glucose uptake, as indicated by uptake of
non-metabolizable 2-deoxy[14C]glucose, increases 8-fold,
suggesting that glucose is the major energy source for the
ACSL1-deficient heart.10 This increase in glucose use results
in diminished AMP-activated kinase activity, an 8-fold
increase in mTORC1 activity, and mTOR-mediated cardiac
hypertrophy.9,10
mTORC1 is a major regulator of cell growth and proliferation
and responds to cellular energy levels, stress, and nutrients,
particularly amino acids and glucose.42 Activation of mTORC1
causes phosphorylation of p70 S6K, which increases protein
synthesis, and 4E binding protein, which promotes protein
translation.43 mTOR kinase activity is suppressed by the
tuberous sclerosis complex 1/2 (TSC1/2). When AMPK is
active, it phosphorylates and activates TSC1/2 so that mTOR is
inactivated. Although AMPK is usually thought of as reacting to
low cellular energy levels, particularly an increased ratio of
AMP to ATP, AMPK activity is down-regulated in Acsl1H/
hearts, despite normal intracellular concentrations of ATP and
AMP.9 Down-regulation of AMPK relieves the TSC1/2-mediated
suppression of mTORC1 and allows it to be active.
Hemodynamic stress increases carbohydrate use and
structural remodeling, both attributable to mTORC1 activa-
tion.44 Mechanical efficiency is said to be impaired when FA
oxidation is high, possibly because the rate of O2 consump-
tion is higher per amount of ATP generated.2,45 In addition,
high cytosolic concentrations of FA are potentially subject to
a futile ATP-wasting cycle via UCP-3 and thioesterases, with a
resulting loss of protons.2 Nevertheless in some instances,
reliance on glucose may be detrimental to function, given
that upregulated mTOR activity promotes hypertrophy and
contractile dysfunction in perfused working hearts.8 Although
the hypertrophy that develops in ACSL1 null hearts is
similarly attributable to mTORC1 activation, because it is
abrogated by rapamycin treatment, diastolic rather than
systolic function is impaired in Acsl1H/ hearts.10
A comprehensive study of gene expression in normal MEFs
and in MEFs with activated mTORC1 because of deficient TSC1
or TSC2 showed major changes related to the S6K-mediated
hypoxia-inducible transcription factor Hif1a and to SREBP1
and SREPB2.14 These transcriptional targets of mTORC1 were
upregulated independent of growth factors and were sup-
pressed by rapamycin; mTORC1-controlled genes included
239 genes that were enriched in pathways of glycolysis, the
pentose phosphate shunt, and FA and cholesterol biosynthe-
sis. mRNAs that increased in the MEFs included those
encoding Glut1, which enhances glucose entry, almost all
the glycolytic and pentose phosphate pathway enzymes, and
enzymes in the pathways of lipid, FA, and sterol synthesis. The
significance of the mRNA upregulation was confirmed by
increased substrate flux through the relevant pathways.
mTORC1 upregulation of Hif1a was responsible for targeting
glycolytic genes and for the increased processing of SREBP1
and SREBP2 to active nuclear forms which regulated the
pentose phosphate pathway and lipid synthesis genes.14
To better understand the metabolic changes that occur
with substrate switching in heart from FA to glucose, and to
determine how these changes were related specifically to
chronically activated mTORC1, we used Acsl1H/ mice to
ask how a fully differentiated tissue would respond to
mTORC1 activation and how closely the changes would
correspond to the alterations found in MEFs with increased
mTORC1.14 We examined gene arrays and tested whether the
increases observed in a subset of upregulated genes would be
diminished when mTOR was inhibited by rapamycin treat-
ment. In addition, we used unbiased metabolomics to identify
changes in cardiac metabolic pathways that occurred when
reliance on glucose for energy was essential. Similar to the
data with activated mTORC1 in MEFs, the gene array obtained
from Acsl1H/ hearts showed upregulated Hif1a, Srebp1
(Srebf1), and several glycolytic genes (eg, Pfkfb1). However, in
Acsl1H/ hearts, genes involved in the pentose shunt and in
FA and sterol synthesis were not altered. Instead, we noted
Figure 5. Metabolomic profiling reveals that loss of Acsl1
expression alters the cardiac metabolite profile. Levels of 115
or 157 metabolites measured by either LC-TOFMS (left) or GC-
TOFMS (right), respectively, were subjected to both unsupervised
(PCA, upper) and supervised (PLS-DA, lower) multivariate data
analysis. Data are represented using scatter plots of the first 2
components and confidence ellipses categorized by genotype
represent 2 standard deviations. GC- and LC-TOFMS indicates gas
chromatography and liquid chromatography-time of flight mass
spectrometry; PCA, principal component analysis; PLS-DA, partial
least squares discriminant analysis.
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striking upregulation of additional mTOR-dependent pathways,
particularly the amino acid responsive genes, peroxisomal
genes, and genes involved in the regulation of apoptosis and
cell stress. Several of these genes have been previously
identified as targets of mTORC1: Fgf21 and Gdf15 are
prominent in CCK-mediated pancreatic growth46 and Gdf15
in ovarian cancer.47 Our study of Acsl1H/ hearts also
showed diminished expression of numerous genes related to
transcriptional regulation and zinc finger factors.
Cardiac stresses like hypertension alter predominant
substrate use from FA to glucose.2 mTORC1 is now seen as
a major cause of cardiac hypertrophy, as it both stimulates
cell growth and inhibits autophagy.48 mTORC1 activation
underlies the hypertrophy that occurs in hypertensive SHR
rats49 and in Acsl1H/ mice that cannot use FA for energy.
Our study in mice is consistent with data from working hearts
showing that perfusion with glucose causes metabolic




Figure 6. Differential metabolite analysis in Acsl1-deficient hearts. A and B, Significance analysis of
metabolites (SAMet) plot of observed scores plotted against the expected scores in heart extracts from
either control or Acsl1H/ mice obtained from the LC-TOFMS (A) or GS-TOFMS (B). The solid line
represents observed=expected, whereas the hashed lines indicate the significance threshold based on
D=1.2. The metabolites identified as significantly different are indicated by red and blue open circles,
indicating higher and lower concentrations, respectively, of these genes in Acsl1H/ relative to control
mouse hearts. The number of differential metabolite concentrations, the number of predicted false
positives, and the false discovery rate (FDR) are provided. C, Unsupervised hierarchical clustering of the
combined LC- GC-TOFMS data set using the differential metabolites identified by SAMet in Acsl1H/ and
control mouse hearts. GC-TOFMS indicates gas chromatography-time of flight mass spectrometry.
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Acsl1H/ mice9 and in isolated rat hearts using glucose and
subjected to an elevated workload,8 activated AMPK
decreases, thereby diminishing phosphorylation of TSC1 and
relieving its inhibition of mTORC1; the resulting increase in
mTORC1 activity induces cardiac hypertrophy.10
Metabolomics analysis has not been extensively used to
gain information about energy pathways in the heart. In
humans with ischemia, increased circulating metabolites
include metabolites related to pyrimidine metabolism, and
the tricarboxylic acid and pentose phosphate pathways.50 A
metabolomic analysis of ventricles from cardiomyopathic
hamsters showed a mild reduction in glutathione and
increased oxidative stress.51 In our study, the upregulation
of 13 metabolites related to cysteine and glutathione
metabolism was unanticipated. Perfusion of working rat
hearts with glucose causes oxidative stress,8 and it is likely
that the altered metabolite and gene expression in Acsl1H/
hearts, as well as increased oxidized glutathione and other
oxidative stress markers analyzed, indicate a response to
oxidative stress initiated by either mTORC1 or another aspect
of the switch in substrate use. The expression of Gsta1 and
Gsta2 was 15-fold higher in Acsl1H/ hearts than controls,
and rapamycin diminished Gsta1 expression dramatically,
consistent with other studies demonstrating induction of
Gsta1 expression in hearts overexpressing GLUT152 and with
induction of Gsta2 expression by mTOR when cells are
stimulated by insulin53,54 or by cytoprotective agents.55
When glucose flux into the heart was enhanced by cardiac-
specific overexpression of the glucose transporter GLUT1,
PPARa expression and FA oxidation were diminished, oxidative
stress increased, and mild contractile dysfunction occurred.32
Similarly, when isolated hearts were perfused with glucose and
subjected to a high workload, mTOR was activated and ER
stress and defective contractile function were induced; the ER
stress and contractile defects were abrogated by pretreatment
with rapamycin, demonstrating the specific role of mTOR in the
manifestation of these cardiac phenotypes.8 Studies using
2-deoxyglucose, which can be converted to 2-deoxyglucose-6-
phosphate but cannot be further metabolized, demonstrated
that conversion of glucose to its phosphorylated product is
required for mTOR activation.56 Thus, the authors concluded
that dependence on glucose use causes metabolic changes





Figure 7. Cardiac-specific Acsl1 deficiency leads to increased
glucose metabolism. A and B, Representative immunoblots against
PDK4, deglycosylated GLUT1 and GAPDH (loading control) from
ventricles of male control and Acsl1H/ mice 10 weeks after
tamoxifen treatment. The ratio of GLUT1 to GAPDH is shown (B,
bottom). The values are meanSEM. n=3 to 4, *P<0.05. C and D,
[1-14C]- and [2-14C]pyruvate oxidation to CO2 from control and
Acsl1H/ ventricular homogenates 10 weeks after tamoxifen




Figure 8. Loss of Acsl1 results in elevated oxidative stress
markers in the heart. A, Representative immunoblots against
GSK-3b, VDAC1 (mitochondrial marker) and GAPDH (cytosolic
marker) from ventricles of male control and Acsl1H/ mice
10 weeks after tamoxifen treatment. The levels of GSK-3b and
VDAC1 were quantified with ImageJ software, the ratio of GSK-3b
to VDAC1 calculated and the percentage of GSK-3b in the
mitochondrial fraction of control and Acsl1H/ mice is shown
(right). The values are meanSEM. n=4, *P<0.05. B, 8-hydroxy-
20deoxyguanosine levels were measured as indication of DNA and
RNA damage in left ventricles of male control and Acsl1H/ mice
10 weeks after tamoxifen treatment. C, Oxidized (GSSG) and
reduced (GSH) levels of glutathione were measured using a
colorimetric kit. The values are meanSEM. n=5 to 6, *P<0.05.
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living mice whose cardiac demand for glucose oxidation is
dramatically enhanced supports this interpretation. In addition,
we show that a deficit in the use of FA for energy causes
numerous major changes in gene expression, many of which,
but not all, can be attributed to mTORC1 activation. Although
substrate switching from FA to glucose did not affect cardiac
systolic function in Acsl1H/ hearts, diastolic function was
impaired.10 Thus, the potential for harm related to oxidative
stress and aberrant physiology suggests that a switch from the
use of FA to glucose may not be entirely benign.
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